Safe use of sodium valproate by Zawab, Ahamed & Carmody, John
University of Wollongong 
Research Online 
Faculty of Science, Medicine and Health - 
Papers: part A Faculty of Science, Medicine and Health 
1-1-2014 
Safe use of sodium valproate 
Ahamed Zawab 
Wollongong Hospital, ahamed@uow.edu.au 
John Carmody 
University of Wollongong, johncar@uow.edu.au 
Follow this and additional works at: https://ro.uow.edu.au/smhpapers 
 Part of the Medicine and Health Sciences Commons, and the Social and Behavioral Sciences 
Commons 
Recommended Citation 
Zawab, Ahamed and Carmody, John, "Safe use of sodium valproate" (2014). Faculty of Science, Medicine 
and Health - Papers: part A. 2102. 
https://ro.uow.edu.au/smhpapers/2102 
Research Online is the open access institutional repository for the University of Wollongong. For further information 
contact the UOW Library: research-pubs@uow.edu.au 
Safe use of sodium valproate 
Abstract 
Valproate is an anticonvulsant drug which is approved for use in epilepsy and bipolar disorder. It has also 
been used for neuropathic pain and migraine prophylaxis. Gastrointestinal adverse effects are common, 
particularly at the start of therapy. Important adverse effects include pancreatitis, hepatitis, weight gain 
and sedation. There is an increased risk of fetal abnormalities if valproate is taken in pregnancy. 
Measuring concentrations of serum valproate is often unnecessary. They do not correlate closely with its 
therapeutic effects. If withdrawal of valproate is required, this should be done slowly if possible. Rapid 
cessation may provoke seizures in patients with epilepsy. 
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Safe use of sodium valproate
SUMMARY
Valproate is an anticonvulsant drug which is approved for use in epilepsy and bipolar disorder. It 
has also been used for neuropathic pain and migraine prophylaxis.
Gastrointestinal adverse effects are common, particularly at the start of therapy. Important 
adverse effects include pancreatitis, hepatitis, weight gain and sedation. There is an increased risk 
of fetal abnormalities if valproate is taken in pregnancy.
Measuring concentrations of serum valproate is often unnecessary. They do not correlate closely 
with its therapeutic effects.
If withdrawal of valproate is required, this should be done slowly if possible. Rapid cessation may 
provoke seizures in patients with epilepsy.
Indications
Although there is clinical experience with valproate in 
epilepsy, some of its other accepted indications, such 
as migraine prophylaxis, have not been approved by 
the Therapeutic Goods Administration.
Epilepsy
Valproate is a broad spectrum antiepileptic drug and 
is used to treat either generalised or focal seizures. 
It is recommended in Australian4 and international5-7 
clinical practice guidelines. There is evidence that it 
is more effective than lamotrigine or topiramate in 
treating:
 • idiopathic generalised epilepsy syndromes
 • seizures that are difficult to classify.8  
Some authors have expressed concern that there 
remains a dearth of well-designed, properly 
conducted, randomised controlled trials for adults 
with generalised seizures/epilepsy syndromes and for 
children in general.5  
Bipolar disorder
Valproate was first used for the maintenance 
treatment of bipolar disorder in Europe in 1966. Over 
the past two decades there has been a dramatic rise 
in its use for this condition.9 However, the authors 
of a recent Cochrane review said that, in view of 
the lack of clear findings in their review and the 
limited available evidence, conclusions regarding the 
efficacy and acceptability of valproate compared to 
placebo or lithium cannot be made with any degree 
of confidence.10 Longer-term and larger sample 
size randomised controlled trials are required to 
better assess the clinical utility of valproate in the 
maintenance therapy of bipolar disorder.10 
Introduction
Sodium valproate (valproate) was first marketed as 
an anticonvulsant almost 50 years ago in France. Its 
indications have expanded and it is now the most 
prescribed antiepileptic drug worldwide.1 However, it 
has many potential adverse effects.
Pharmacology
Valproate is available in tablet (immediate-release or 
enteric coated), syrup and intravenous formulations. 
There is no single mechanism of action that can 
explain valproate’s broad effects on neuronal tissue. 
Its pharmacological effects include: 
 • increased gamma-aminobutyric acid transmission
 • reduced release of excitatory amino acids
 • blockade of voltage-gated sodium channels
 • modulation of dopaminergic and serotonergic 
transmission.2  
When fasting, oral valproate is rapidly absorbed 
and reaches peak plasma concentrations within four 
hours (immediate-release formulation) to seven 
hours (enteric coated formulation). It is highly plasma 
protein bound and has a half-life of 8–20 hours in 
most patients, but this may occasionally be much 
longer, for example in renal impairment or overdose.3 
The relationship between dose, plasma concentration 
and therapeutic effect is not well understood. 
Valproate is almost completely metabolised in the 
liver, mainly by glucuronidation. It then undergoes 
further metabolism with oxidation, which is complex 
and involves several cytochrome P450 enzyme 
systems. It has multiple metabolites which may 
contribute to both its efficacy and toxicity. There are 
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Contraindications and precautions
Valproate should be avoided in patients with liver 
disease or a family history of liver disease. Although 
uncommon, patients with a urea cycle disorder 
or porphyria should also avoid valproate. Renal 
failure can impair protein binding and lead to the 
accumulation of metabolites, so a lower dose may be 
required in patients with impaired renal function.
Routine laboratory studies should be performed 
before commencing therapy, but regular monitoring is 
not required for most patients.6 The onset of lethargy, 
vomiting or ataxia is an indication to measure 
serum ammonia to exclude hyperammonaemic 
encephalopathy. Spontaneous bruising or bleeding 
may occur and necessitates clinical review and 
investigation. Such patients may have developed 
thrombocytopenia or altered platelet function. 
Pregnancy and lactation
Maternal exposure to valproate was first linked to an 
increased risk of congenital spina bifida in the 1980s. 
Valproate has an increased risk of major congenital 
malformations and poor cognitive outcomes 
compared to other antiepileptic drugs.14 
In the Australian categorisation system valproate is 
in pregnancy category D, so women of childbearing 
age should use effective contraception (e.g. oral 
contraceptive, intrauterine device, subdermal 
etonogestrel). The safe use of valproate in women of 
childbearing age is fraught with challenges.15 Ideally, 
the indications for using valproate should be reviewed 
and its risks discussed before pregnancy occurs.
A recent systematic review16 of the teratogenicity of 
antiepileptic drugs advised clinicians to:
 • avoid valproate if equally effective antiepileptic 
drugs are available
 • aim for monotherapy
 • prescribe the lowest effective dose whenever 
possible, avoid valproate doses of 700 mg daily or 
above (if possible)
 • avoid withdrawal or changes of antiepileptic drugs 
after conception has occurred. 
The FDA has announced that valproate is 
contraindicated for the prevention of migraine during 
pregnancy. It should only be used during pregnancy 
by women with epilepsy or bipolar disorder if other 
drugs are ineffective or unacceptable.
Folic acid supplementation (at least 0.4 mg daily), one 
month pre-conception and during the first trimester, 
is recommended for all women to reduce the risk of 
fetal neural tube defects. Women taking antiepileptic 
drugs, particularly valproate, are at greater risk of 
having a child with neural tube defects and other 
Neuropathic pain
Although the guidelines of the UK National Institute 
for Health and Care Excellence11 do not recommend 
valproate for neuropathic pain, an American  
Academy of Neurology practice parameter12 suggests 
that it should be considered for the treatment of 
painful diabetic neuropathy. A Cochrane review 
concluded that, in view of the limited available 
evidence, valproate use should be reserved for  
cases of neuropathic pain where other proven 
treatment options have failed, are not available,  
or are not tolerated.1
Migraine
Preventative therapy for migraine is often undertaken 
if patients have more than one attack per month. 
First-line drugs for migraine prophylaxis include 
amitriptyline, propranolol and pizotifen. A systematic 
review found that valproate is also effective in 
reducing migraine frequency and is reasonably 
well tolerated.3 
Adverse reactions
Common adverse effects of valproate include nausea, 
upper abdominal cramps, abnormal liver function, 
weight gain and diarrhoea. Neurological adverse 
effects such as tremor, fatigue, sedation, confusion 
and dizziness are often observed. Other potential 
adverse effects include alopecia, reduced bone 
density, thrombocytopenia, anaemia, leucopenia and 
hyperammonaemia. 
There are several cutaneous adverse effects of 
valproate. They include pruritus, urticaria, erythema 
multiforme, toxic epidermal necrolysis, Stevens-
Johnson syndrome, and drug reaction with 
eosinophilia and systemic symptoms (DRESS). 
Cases of polycystic ovarian syndrome and male 
infertility have also been reported. 
There is a risk of hepatic dysfunction (>1%) and 
pancreatitis (<0.1%). Both adverse effects can be 
fatal. If liver failure occurs, it is usually in the first 
six months, but pancreatitis can occur after years of 
use. Although liver function tests may alter during 
treatment they are not reliable in predicting which 
patients will develop liver failure.
A pooled analysis of 199 clinical trials of 11 antiepileptic 
drugs (including valproate) by the US Food and Drug  
Administration (FDA) found that patients who were  
randomised to receive an antiepileptic drug had almost 
twice the risk of suicidal behaviour or ideation (0.43%) 
compared to patients randomised to receive placebo 
(0.24%).13 This suggests that there would be one 
additional case of suicidal thinking or behaviour for 
every 530 patients treated with any antiepileptic drug.13 
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range from mild to life-threatening. Of particular 
clinical relevance is valproate’s effect on other 
antiepileptic drugs (for example carbamazepine, 
lamotrigine, phenobarbitone, phenytoin, topiramate).
Drug monitoring
With the exception of phenytoin (and possibly 
lamotrigine), antiepileptic drugs do not require 
routine therapeutic drug monitoring assays.6,19 
Although measuring serum valproate concentrations 
may be useful in screening patients for toxicity20 
or poor compliance, there is little evidence linking 
concentration to clinical efficacy.19,21 A retrospective 
study within a major Australian teaching 
hospital found that most requests were ordered 
inappropriately and many tests were not taken at the 
correct time (at least eight hours after the last dose).21 
Signs and management of toxicity 
The majority of patients with acute valproate 
intoxication experience mild to moderate lethargy 
and recover uneventfully. Central nervous system 
dysfunction is the most common manifestation of 
toxicity and this can range in severity from mild 
drowsiness to coma or fatal cerebral oedema. 
Hypernatraemia, metabolic acidosis, hyperammonaemia 
and liver failure may develop in some patients. 
Toxicity can occur within the therapeutic range and 
includes hyperammonaemic encephalopathy. This can 
present with confusion, increased seizures and focal 
neurological signs.
Supportive care is the principal treatment for 
valproate intoxication and results in good outcomes 
in the vast majority of cases. Activated charcoal may 
be considered for alert patients who have taken a 
severe overdose.22
Withdrawal
Some doctors favour a gradual withdrawal of 
antiepileptic drugs (for example over a six-month 
period) to lessen the risk of seizure recurrence.23 
However, a Cochrane review has highlighted the 
lack of evidence to guide clinicians on the optimal 
rate of withdrawal in patients whose seizures are 
well controlled.24 There is little evidence to guide 
antiepileptic drug withdrawal tapering periods in non-
epileptic patients.
The Austroads Assessing Fitness to Drive guide 
recommends that private licence holders do not drive 
while withdrawing antiepileptic drugs and for three 
months afterwards.25 Commercial licence holders 
with epilepsy will not be eligible to drive if their 
antiepileptic drug is ceased. The Austroads guidelines 
do not specifically address antiepileptic drug 
withdrawal by patients without epilepsy.25
malformations which may be related to altered folate 
metabolism. Consequently, they require a higher 
dose of folic acid supplementation (5 mg daily).17 An 
American Academy of Neurology systematic review 
of the available literature concluded that, although 
the data are insufficient to show that folic acid 
supplementation is effective in women with epilepsy, 
there is no evidence of harm and no reason to suspect 
that it would not be effective in this group.14
Although valproate probably does not enter breast 
milk in clinically important amounts,14,18 the drug’s 
manufacturers advise against breastfeeding. 
Women with epilepsy who are currently pregnant 
or who have given birth recently are encouraged to 
contact the Australian Pregnancy Register at  
www.neuroscience.org.au/apr or 1800 069 722. 
Drug interactions
For a variety of pharmacokinetic and 
pharmacodynamic reasons, valproate use has the 
potential to interact with a large number of drugs 
(see Box). The consequences of such interactions 
Box    Potential drug interactions with 
valproate
aspirin
large doses increase valproate concentration
carbamazepine
reduces valproate concentration





valproate increases lamotrigine concentration (risk of 
Stevens-Johnson syndrome)
olanzapine
valproate decreases olanzapine concentration
phenobarbitone
reduces valproate concentration
valproate increases phenobarbitone concentration
phenytoin
reduces valproate concentration
valproate increases phenytoin concentration (initially free, 
later total) 
topiramate
increases the risk of valproate-associated adverse effects 
(e.g. hyperammonaemia)
zidovudine
valproate increases zidovudine concentration 
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Conclusion
Valproate has been prescribed widely for decades. 
Given that new indications continue to emerge, it 
is increasingly important for clinicians to remain 
cognisant of the drug’s adverse effects. A key 
component of safe valproate use involves the 
provision of tailored counselling and education to 
each patient before starting therapy. 
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SELF-TEST 
QUESTIONS
True or false? 
3. Patients with epilepsy 
should have their serum 
valproate concentration 
measured at least once 
a year
4. Liver function 
tests can be used to 
predict patients at 
risk of hepatic failure 
during treatment with 
valproate
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